2025-10-09 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX) based on the provided data.

**Report on Recursion Pharmaceuticals (RXRX)**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** RXRX
*   **Company:** Recursion Pharmaceuticals Inc. (Recursion Pharmaceuticals is a clinical-stage biotechnology company using AI and machine learning to discover and develop drugs.)

**Key Numbers:**

*   RXRX Cumulative Return: -2.78%
*   VOO Cumulative Return: 41.60%
*   Relative Divergence:
    *   Current: -52.8
    *   Min: -64.3
    *   Max: 84.1
    *   Relative Position (0-100): 7.7

**Analysis:** Recursion Pharmaceuticals has significantly underperformed the S&P 500 (VOO) over the period examined. The current relative divergence of -52.8 indicates RXRX is lagging the benchmark. The relative position of 7.7 suggests that the current divergence is near the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2021-2023  | 22.0%  | 81.0% | 26.0%  | -0.2  | 4.3    |
| 2022-2024  | 11.0%  | 81.0% | -10.0% | 0.1   | 3.0    |
| 2023-2025  | 40.0%  | 80.0% | -24.0% | 0.1   | 2.7    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate varies significantly across different periods, indicating inconsistent performance.
*   **MDD:** The Maximum Drawdown is consistently high (around 80%), suggesting substantial risk.
*   **Alpha:** Alpha is inconsistent, shifting from positive to negative, indicating underperformance relative to its risk-adjusted expected return.
*   **Beta:** Beta is low, suggesting low correlation with the overall market.

**2. Recent Price Action**

*   Current Price: $6.09
*   Last Market Data: Price: $6.09, Previous Close: $5.23, Change: +16.44% (Significant increase)
*   5-Day Moving Average: $5.572
*   20-Day Moving Average: $5.0352
*   60-Day Moving Average: $5.2685

**Analysis:** The stock experienced a substantial price increase (+16.44%) compared to the previous close. The current price is above all three moving averages, suggesting a short-term bullish trend.

**3. Market Risk Indicator (MRI) and Other Indicators**

*   MRI: 0.9 (High Investment Recommended)
*   RSI: 72.57 (Approaching overbought territory)
*   PPO: 2.40
*   Hybrid Signal: cash_0%_Buy 100% of cash (195 shares - Very Safe - MRI:0.90) Monthly invest 1.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   Recent (20-day) Relative Divergence Change: +7.5 (Short-term increase)
*   Expected Return: -52.2% (Long-term, relative to S&P 500)

**Analysis:** The MRI suggests a high investment recommendation, while the RSI indicates the stock is approaching overbought conditions. The positive change in relative divergence suggests recent outperformance compared to its historical trend. However, the negative expected return indicates potential underperformance relative to the S&P 500 over the long term. The large price change likely influences these indicators, signaling a short-term reactive movement.

**4. Recent News & Significant Events (Yahoo Finance)**

*   **Positive Sentiment:**
    *   Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory (Insider Monkey)
    *   Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
    *   Evaluating Recursion After a 19% Rally Amid Renewed Interest in Biotech AI Initiatives (Simply Wall St.)
    *   Needham Reiterates a Buy on Recursion Pharmaceuticals (RXRX) (Insider Monkey)
*   **Mixed/Cautionary:**
    *   Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know (Zacks)
    *   Jim Cramer on Recursion: “I Need to See a Proof of Concept Here” (Insider Monkey)

**Analysis:** Recent news presents a mixed picture. Some articles highlight a bull case and recent surges, indicating positive sentiment and renewed interest in biotech AI initiatives. However, other articles point out underperformance compared to the broader market and caution regarding the need for proof of concept.

**4-2. Analyst Opinions:**

*   Consensus: Hold
*   Mean Rating: 2.62 (~Hold)
*   Opinions: 6
*   Target Price (avg/high/low): 6.47 / 10.00 / 3.00
*   Recent Rating Changes: No changes provided

**Analysis:** Analyst consensus is a "Hold" rating with a mean rating close to Hold. The average target price of $6.47 suggests a moderate upside potential from the current price, while the wide range between the high and low target prices indicates uncertainty.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출    |
|------------|-------|---------|
| 2025-08-05 | -0.41 | 0.02 B$ |
| 2025-05-05 | -0.5  | 0.01 B$ |
| 2024-11-06 | -0.34 | 0.03 B$ |
| 2024-08-08 | -0.4  | 0.01 B$ |
| 2025-08-05 | -0.4  | 0.01 B$ |

**Analysis:** The company has consistently reported negative EPS, indicating losses. Revenue has fluctuated between $0.01B and $0.03B over the past few quarters.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.02B  | -5.54%        |
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |
| 2024-06-30 | $0.01B  | 36.14%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE       |
|------------|---------|-----------|
| 2025-06-30 | $0.92B  | -18.70%   |
| 2025-03-31 | $0.93B  | -21.68%   |
| 2024-12-31 | $1.03B  | -17.29%   |
| 2024-09-30 | $0.52B  | -18.27%   |
| 2024-06-30 | $0.58B  | -16.69%   |

**Analysis:** Revenue is inconsistent. Profit margins are highly volatile, with some quarters showing positive margins, and others exhibiting significant losses. ROE is consistently negative, reflecting the company's inability to generate profits from its equity.

**7. Overall Summary**

Recursion Pharmaceuticals (RXRX) presents a mixed investment picture:

*   **Underperformance:** The stock has significantly underperformed the S&P 500.
*   **High Risk:** The high Maximum Drawdown and negative expected return highlight the stock's risk.
*   **Inconsistent Financials:** Revenue and profit margins are volatile, and the company is consistently reporting losses.
*   **Positive Catalysts:** Recent news shows renewed interest in Biotech/AI initiatives and analyst reiterations of "Buy" ratings exist. However, there is a call for a "Proof of Concept"
*   **Short-Term Bullish Signals:** Recent price surge, MRI indicator, and positive change in relative divergence suggest a possible short-term uptrend.

**Conclusion:**

RXRX is a high-risk, high-reward investment. The company shows promise with its AI-driven drug discovery platform, but it needs to demonstrate a clear path to profitability. Recent positive news may be driving a short-term rally.
